Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Abiomed Inc., liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
- Current Ratio
- The current ratio demonstrates a generally strong liquidity position throughout the periods observed, consistently remaining above 4.5 and frequently exceeding 6. Early data points in 2016 show a high ratio near 7, followed by a gradual decline in 2017, reaching lows near 4.7 by the first quarter of 2017. Subsequently, the ratio rebounds to a peak above 6.8 in late 2020 and again reaches a high point of nearly 8 by the third quarter of 2022. This pattern indicates cyclical fluctuations but an overall sustained ability to cover short-term liabilities with current assets.
- Quick Ratio
- The quick ratio trends largely mirror those of the current ratio, confirming a strong liquidity profile without reliance on inventory. Starting above 6 in mid-2016, it decreases through 2017 reaching a low around 4 by the first quarter of 2020, signifying a reduction in the most liquid current assets relative to liabilities. However, post-2020 data shows a recovery with the ratio climbing back above 6 by the latter part of 2021 and continuing upward to nearly 6.8 in late 2022. This trend reflects prudent management of liquid assets to maintain short-term financial stability.
- Cash Ratio
- The cash ratio, representing the most conservative liquidity measure, shows more pronounced variability. Initially above 5 in mid-2016, it declines to slightly above 3.3 in early 2017 and remains around this level until the first quarter of 2020, indicating a lower proportion of cash relative to current liabilities during this period. Afterward, there is a noticeable improvement with values rising above 5 from late 2020 onward, culminating near 6.1 in the third quarter of 2022. The upward trend suggests enhanced cash reserves or equivalent holdings relative to short-term obligations in the recent periods.
- Overall Insights
- Across all three liquidity ratios, a cyclical pattern is evident with an initial decline during 2016-2017 followed by gradual recovery through to 2022. The strong values of the current and quick ratios emphasize the company's solid short-term financial health. The improvement in the cash ratio in recent years demonstrates a strategic emphasis on maintaining readily available cash or equivalents, which could be due to a more conservative liquidity approach or preparation for uncertain market conditions. These liquidity trends collectively depict a company capable of meeting its short-term liabilities comfortably while actively managing its liquid asset holdings.
Current Ratio
Abiomed Inc., current ratio calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Current assets | 1,062,798) | 1,060,359) | 976,473) | 885,006) | 871,487) | 729,873) | 787,965) | 693,691) | 716,621) | 619,689) | 635,863) | 636,576) | 647,432) | 677,365) | 677,197) | 628,728) | 561,599) | 497,297) | 494,271) | 422,198) | 370,170) | 350,915) | 326,958) | 333,419) | 319,870) | 300,288) | ||||||||
| Current liabilities | 134,060) | 140,762) | 138,457) | 126,796) | 114,022) | 113,123) | 128,969) | 120,400) | 105,213) | 110,379) | 131,885) | 126,259) | 112,229) | 100,201) | 105,998) | 92,980) | 81,979) | 76,678) | 84,682) | 75,353) | 63,358) | 59,005) | 69,617) | 58,871) | 51,922) | 43,219) | ||||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||||||
| Current ratio1 | 7.93 | 7.53 | 7.05 | 6.98 | 7.64 | 6.45 | 6.11 | 5.76 | 6.81 | 5.61 | 4.82 | 5.04 | 5.77 | 6.76 | 6.39 | 6.76 | 6.85 | 6.49 | 5.84 | 5.60 | 5.84 | 5.95 | 4.70 | 5.66 | 6.16 | 6.95 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 1.64 | 1.68 | 1.63 | 1.86 | 2.01 | 1.85 | 1.85 | 1.83 | 1.79 | 1.75 | 1.72 | 1.70 | 1.57 | 1.43 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 1.44 | 1.43 | 1.40 | 1.35 | 1.36 | 1.36 | 1.47 | 1.48 | 1.49 | 1.57 | 1.55 | 1.59 | 1.64 | 1.53 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 5.22 | 5.26 | 4.40 | 5.10 | 5.36 | 5.22 | 5.08 | 5.58 | 5.99 | 6.71 | 6.86 | 7.04 | 6.38 | 4.96 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 1.76 | 1.58 | 1.86 | 2.61 | 2.91 | 2.89 | 2.65 | 2.10 | 2.16 | 1.87 | 2.13 | 2.75 | 2.77 | 2.67 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.80 | 0.81 | 0.77 | 0.82 | 0.77 | 0.78 | 0.79 | 0.77 | 0.77 | 0.74 | 0.74 | 0.82 | 0.84 | 0.75 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 1,062,798 ÷ 134,060 = 7.93
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in liquidity and working capital management over the observed periods.
- Current Assets
- The current assets demonstrate a general upward trend throughout the time frame. Starting at approximately $300.3 million at mid-2016, current assets increased steadily, reaching over $1 billion by mid-2022. There are periods of more rapid growth, particularly noticeable between late 2017 and mid-2019, and again from late 2020 through mid-2022, indicating a possible accumulation of cash, receivables, or other liquid assets during these intervals. Occasional minor declines or plateaus are present but are short-lived and followed by subsequent increases.
- Current Liabilities
- Current liabilities also show an increasing pattern over time but with more variability compared to current assets. Beginning at around $43.2 million in mid-2016, current liabilities rise to approximately $134.1 million by late 2022. There are fluctuations within this increase; some quarters exhibit declines or slower growth, particularly around late 2020 and portions of 2021, suggesting periods of reduction or stabilization in short-term obligations. Despite these fluctuations, the general direction is upward throughout the timeline.
- Current Ratio
- The current ratio, which measures short-term solvency by comparing current assets to current liabilities, illustrates a relatively high and stable liquidity position across the quarters. It begins at a very strong level of nearly 7 times in mid-2016, experiences some declines reaching a low near 4.7 at the beginning of 2017, and then fluctuates between approximately 5 and 7.9 for the remainder of the periods. The ratio’s tendency to remain well above the traditional benchmark of 1.0 indicates consistent ability to cover current liabilities with current assets.
Overall, the data suggests robust liquidity with current assets growing at a stronger pace than current liabilities, supporting an improving or at least well-maintained working capital position. While current liabilities have increased, the current ratio's maintenance at high levels implies effective management of short-term obligations relative to liquid resources. The fluctuations in the current ratio highlight variations in quarterly cash flow cycles or operational needs but do not indicate any liquidity distress across the analyzed periods.
Quick Ratio
Abiomed Inc., quick ratio calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Cash and cash equivalents | 182,335) | 180,492) | 132,818) | 144,255) | 241,882) | 175,454) | 232,710) | 181,018) | 202,241) | 214,827) | 192,341) | 117,970) | 150,279) | 101,048) | 121,021) | 84,181) | 76,382) | 61,288) | 42,975) | 50,502) | 44,536) | 43,970) | 39,040) | 61,069) | 54,709) | 38,274) | ||||||||
| Short-term marketable securities | 638,037) | 663,829) | 625,789) | 524,966) | 408,677) | 347,577) | 350,985) | 305,434) | 330,843) | 212,536) | 250,775) | 309,569) | 295,041) | 385,624) | 370,677) | 373,975) | 334,064) | 299,228) | 319,274) | 250,751) | 218,661) | 207,441) | 190,908) | 179,640) | 178,236) | 184,900) | ||||||||
| Accounts receivable, net | 94,475) | 91,102) | 90,608) | 88,952) | 89,568) | 88,645) | 97,179) | 92,990) | 80,909) | 82,084) | 84,650) | 100,994) | 94,319) | 86,206) | 90,809) | 88,215) | 74,201) | 67,511) | 70,010) | 64,862) | 57,327) | 53,557) | 54,055) | 50,178) | 46,607) | 41,280) | ||||||||
| Total quick assets | 914,847) | 935,423) | 849,215) | 758,173) | 740,127) | 611,676) | 680,874) | 579,442) | 613,993) | 509,447) | 527,766) | 528,533) | 539,639) | 572,878) | 582,507) | 546,371) | 484,647) | 428,027) | 432,259) | 366,115) | 320,524) | 304,968) | 284,003) | 290,887) | 279,552) | 264,454) | ||||||||
| Current liabilities | 134,060) | 140,762) | 138,457) | 126,796) | 114,022) | 113,123) | 128,969) | 120,400) | 105,213) | 110,379) | 131,885) | 126,259) | 112,229) | 100,201) | 105,998) | 92,980) | 81,979) | 76,678) | 84,682) | 75,353) | 63,358) | 59,005) | 69,617) | 58,871) | 51,922) | 43,219) | ||||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||||||
| Quick ratio1 | 6.82 | 6.65 | 6.13 | 5.98 | 6.49 | 5.41 | 5.28 | 4.81 | 5.84 | 4.62 | 4.00 | 4.19 | 4.81 | 5.72 | 5.50 | 5.88 | 5.91 | 5.58 | 5.10 | 4.86 | 5.06 | 5.17 | 4.08 | 4.94 | 5.38 | 6.12 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 1.00 | 1.07 | 1.06 | 1.22 | 1.33 | 1.21 | 1.28 | 1.25 | 1.19 | 1.16 | 1.14 | 1.01 | 0.93 | 0.83 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 1.32 | 1.31 | 1.27 | 1.21 | 1.22 | 1.23 | 1.33 | 1.33 | 1.35 | 1.43 | 1.42 | 1.45 | 1.49 | 1.37 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 4.36 | 4.30 | 3.56 | 4.19 | 4.49 | 4.40 | 4.34 | 4.66 | 5.12 | 5.76 | 5.96 | 5.93 | 5.40 | 4.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 1.18 | 1.01 | 1.30 | 1.87 | 2.07 | 2.06 | 1.91 | 1.58 | 1.63 | 1.37 | 1.50 | 2.05 | 2.02 | 1.95 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.74 | 0.75 | 0.70 | 0.77 | 0.71 | 0.72 | 0.72 | 0.71 | 0.71 | 0.68 | 0.68 | 0.75 | 0.76 | 0.66 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 914,847 ÷ 134,060 = 6.82
2 Click competitor name to see calculations.
- Total Quick Assets
- The total quick assets demonstrate an overall upward trend from June 2016 through September 2022. Starting at approximately $264 million, there is consistent growth with some fluctuations, reaching a peak of around $935 million by June 2022 before experiencing a slight decline to approximately $915 million in September 2022. Periods such as from March 2020 to September 2020 show a temporary dip, but the general direction remains positive, indicating an expansion in liquid assets over the time frame.
- Current Liabilities
- Current liabilities also increase progressively over the observed quarters, beginning at about $43 million in June 2016 and rising to approximately $134 million by September 2022. The increase is more gradual with periodic increments, the highest levels being noted during 2020 and 2022. Notably, the rise in liabilities is less steep compared to the growth of quick assets, suggesting controlled management of short-term obligations relative to available liquid resources.
- Quick Ratio
- The quick ratio exhibits variability but maintains a generally strong position above 4.0 throughout the period. Initially high at 6.12 in June 2016, it declines to a low of 4.0 in March 2020, coinciding with the minor dips observed in quick assets and the rise in current liabilities during the same period. After this, the ratio recovers and trends upward, surpassing previous highs, reaching 6.82 by September 2022. This indicates stable liquidity with the ability to cover current liabilities with quick assets, yet with some volatility around early 2020 likely reflecting market or operational impacts at that time.
Cash Ratio
Abiomed Inc., cash ratio calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Cash and cash equivalents | 182,335) | 180,492) | 132,818) | 144,255) | 241,882) | 175,454) | 232,710) | 181,018) | 202,241) | 214,827) | 192,341) | 117,970) | 150,279) | 101,048) | 121,021) | 84,181) | 76,382) | 61,288) | 42,975) | 50,502) | 44,536) | 43,970) | 39,040) | 61,069) | 54,709) | 38,274) | ||||||||
| Short-term marketable securities | 638,037) | 663,829) | 625,789) | 524,966) | 408,677) | 347,577) | 350,985) | 305,434) | 330,843) | 212,536) | 250,775) | 309,569) | 295,041) | 385,624) | 370,677) | 373,975) | 334,064) | 299,228) | 319,274) | 250,751) | 218,661) | 207,441) | 190,908) | 179,640) | 178,236) | 184,900) | ||||||||
| Total cash assets | 820,372) | 844,321) | 758,607) | 669,221) | 650,559) | 523,031) | 583,695) | 486,452) | 533,084) | 427,363) | 443,116) | 427,539) | 445,320) | 486,672) | 491,698) | 458,156) | 410,446) | 360,516) | 362,249) | 301,253) | 263,197) | 251,411) | 229,948) | 240,709) | 232,945) | 223,174) | ||||||||
| Current liabilities | 134,060) | 140,762) | 138,457) | 126,796) | 114,022) | 113,123) | 128,969) | 120,400) | 105,213) | 110,379) | 131,885) | 126,259) | 112,229) | 100,201) | 105,998) | 92,980) | 81,979) | 76,678) | 84,682) | 75,353) | 63,358) | 59,005) | 69,617) | 58,871) | 51,922) | 43,219) | ||||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||||||
| Cash ratio1 | 6.12 | 6.00 | 5.48 | 5.28 | 5.71 | 4.62 | 4.53 | 4.04 | 5.07 | 3.87 | 3.36 | 3.39 | 3.97 | 4.86 | 4.64 | 4.93 | 5.01 | 4.70 | 4.28 | 4.00 | 4.15 | 4.26 | 3.30 | 4.09 | 4.49 | 5.16 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.57 | 0.66 | 0.66 | 0.74 | 0.75 | 0.65 | 0.78 | 0.75 | 0.71 | 0.67 | 0.60 | 0.46 | 0.46 | 0.34 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.92 | 0.91 | 0.86 | 0.87 | 0.86 | 0.86 | 0.95 | 0.97 | 0.97 | 1.08 | 1.04 | 1.04 | 1.10 | 0.95 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 3.77 | 3.59 | 2.90 | 3.50 | 3.78 | 3.58 | 3.66 | 3.98 | 4.42 | 5.04 | 5.30 | 5.27 | 4.85 | 3.44 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.79 | 0.63 | 0.85 | 1.26 | 1.37 | 1.36 | 1.27 | 1.17 | 1.18 | 0.99 | 1.06 | 1.33 | 1.27 | 1.25 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.44 | 0.43 | 0.36 | 0.46 | 0.36 | 0.37 | 0.36 | 0.35 | 0.35 | 0.33 | 0.33 | 0.37 | 0.42 | 0.35 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 820,372 ÷ 134,060 = 6.12
2 Click competitor name to see calculations.
The data reveals evolving financial patterns over several years with respect to cash assets, current liabilities, and the cash ratio. Overall, total cash assets exhibit a clear upward trajectory with some fluctuations, while current liabilities tend to increase gradually, and the cash ratio varies over time but remains relatively strong.
- Total Cash Assets
- Total cash assets consistently increased from approximately $223 million in mid-2016 to a peak of about $844 million by mid-2022. This upward trend signifies a substantial accumulation of liquid resources over the analyzed period. While some quarters experienced slower growth or mild declines, the overall trend underscores a strengthening liquidity position. Notably, significant jumps are observable between late 2019 through 2021, indicating periods of robust cash accumulation.
- Current Liabilities
- Current liabilities have shown a general increasing trend from around $43 million in mid-2016 to roughly $135 million by late 2022, indicating a growing short-term obligation load. Despite this growth, liabilities increased at a lower rate compared to total cash assets. Periods of moderate decrease and stabilization can be noted, such as in early to mid-2020, likely reflecting specific operational or market influences during those intervals.
- Cash Ratio
- The cash ratio, which measures the ability to cover current liabilities with cash and cash equivalents, illustrates variability but remains relatively high throughout the timeframe. Starting at 5.16 in mid-2016, it generally fluctuates between approximately 3.3 and 6.1, with peaks in mid-2021 and mid-2022. This suggests a consistently strong liquidity cushion, with cash holdings often exceeding current liabilities by multiple times. Periods where the cash ratio dips near 3.3, including early 2017 and early 2020, still indicate a comfortable liquidity position.
In summary, the data indicates a robust and growing liquidity reserve, supported by rising cash holdings outpacing the growth in short-term liabilities. The company maintains a strong cash ratio, reflecting solid capability to meet immediate obligations. The trends suggest prudent cash management and financial stability across the observed periods.